TipRanks
Oruka Therapeutics (ORKA)
NASDAQ:ORKA
US Market
ORKA
Oruka Therapeutics
RESEARCH TOOLSreports
Want to see ORKA full AI Analyst Report?

Oruka Therapeutics (ORKA) Stock Forecast & Price Target

848 Followers
See the Price Targets and Ratings of:

ORKA Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Oruka
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ORKA Stock 12 Month Forecast

Average Price Target

$154.09
▲(54.96% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Oruka Therapeutics in the last 3 months. The average price target is $154.09 with a high forecast of $200.00 and a low forecast of $120.00. The average price target represents a 54.96% change from the last price of $99.44.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","201":"$201","60.75":"$60.8","107.5":"$107.5","154.25":"$154.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":154.0909090909091,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$154.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$120.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,60.75,107.5,154.25,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.11,100.40923076923077,108.70846153846153,117.00769230769231,125.30692307692308,133.60615384615386,141.9053846153846,150.20461538461538,158.50384615384615,166.80307692307693,175.1023076923077,183.40153846153845,191.70076923076925,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.11,96.87776223776224,101.64552447552447,106.41328671328671,111.18104895104895,115.94881118881119,120.71657342657343,125.48433566433566,130.2520979020979,135.01986013986016,139.78762237762237,144.5553846153846,149.32314685314685,{"y":154.0909090909091,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.11,94.25538461538461,96.40076923076923,98.54615384615384,100.69153846153846,102.83692307692307,104.98230769230769,107.12769230769231,109.27307692307693,111.41846153846154,113.56384615384616,115.70923076923077,117.85461538461539,{"y":120,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.69,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.43,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.51,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.11,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$200.00Average Price Target$154.09Lowest Price Target$120.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on ORKA
David Nierengarten
Wedbush
Wedbush
$165
Buy
65.93%
Upside
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (NASDAQ: ORKA) and Co-Diagnostics (NASDAQ: CODX)
H.C. Wainwright Analyst forecast on ORKA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$120
Buy
20.68%
Upside
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Oruka Therapeutics (NASDAQ: ORKA) and Harmony Biosciences Holdings (NASDAQ: HRMY)
LifeSci Capital Analyst forecast on ORKA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$175
Buy
75.99%
Upside
Reiterated
09/23/26
Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)
Clear Street Analyst forecast on ORKA
Kaveri Pohlman
Clear Street
Clear Street
$131
Buy
31.74%
Upside
Reiterated
09/23/26
Oruka Therapeutics ORKA-001 data meet base case, says Clear StreetOruka Therapeutics ORKA-001 data meet base case, says Clear Street
Barclays Analyst forecast on ORKA
Etzer Darout
Barclays
Barclays
$160
Buy
60.90%
Upside
Reiterated
09/21/26
Barclays Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)
UBS Analyst forecast on ORKA
Michael Yee
UBS
UBS
$130
Buy
30.73%
Upside
Reiterated
09/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS) and Oruka Therapeutics (NASDAQ: ORKA)
TD Cowen Analyst forecast on ORKA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/26/26
Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines
Piper Sandler Analyst forecast on ORKA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$180
Buy
81.01%
Upside
Reiterated
08/17/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Immuneering (IMRX)
Jefferies Analyst forecast on ORKA
Roger Song
Jefferies
Jefferies
$133
Buy
33.75%
Upside
Reiterated
08/11/26
Jefferies Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
BTIG Analyst forecast on ORKA
Julian Harrison
BTIG
BTIG
$151
Buy
51.85%
Upside
Reiterated
08/10/26
Oruka Therapeutics: Strong Clinical Momentum and Pipeline Optionality Support Buy Rating and Unchanged $151 Price Target
Guggenheim Analyst forecast on ORKA
Yatin Suneja
Guggenheim
Guggenheim
$200
Buy
101.13%
Upside
Reiterated
08/10/26
Guggenheim Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
Stifel Nicolaus Analyst forecast on ORKA
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$150
Buy
50.84%
Upside
Reiterated
06/29/26
Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)
Leerink Partners Analyst forecast on ORKA
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on ORKA
David Nierengarten
Wedbush
Wedbush
$165
Buy
65.93%
Upside
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (NASDAQ: ORKA) and Co-Diagnostics (NASDAQ: CODX)
H.C. Wainwright Analyst forecast on ORKA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$120
Buy
20.68%
Upside
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), Oruka Therapeutics (NASDAQ: ORKA) and Harmony Biosciences Holdings (NASDAQ: HRMY)
LifeSci Capital Analyst forecast on ORKA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$175
Buy
75.99%
Upside
Reiterated
09/23/26
Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)
Clear Street Analyst forecast on ORKA
Kaveri Pohlman
Clear Street
Clear Street
$131
Buy
31.74%
Upside
Reiterated
09/23/26
Oruka Therapeutics ORKA-001 data meet base case, says Clear StreetOruka Therapeutics ORKA-001 data meet base case, says Clear Street
Barclays Analyst forecast on ORKA
Etzer Darout
Barclays
Barclays
$160
Buy
60.90%
Upside
Reiterated
09/21/26
Barclays Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)
UBS Analyst forecast on ORKA
Michael Yee
UBS
UBS
$130
Buy
30.73%
Upside
Reiterated
09/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS) and Oruka Therapeutics (NASDAQ: ORKA)
TD Cowen Analyst forecast on ORKA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/26/26
Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines
Piper Sandler Analyst forecast on ORKA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$180
Buy
81.01%
Upside
Reiterated
08/17/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Immuneering (IMRX)
Jefferies Analyst forecast on ORKA
Roger Song
Jefferies
Jefferies
$133
Buy
33.75%
Upside
Reiterated
08/11/26
Jefferies Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
BTIG Analyst forecast on ORKA
Julian Harrison
BTIG
BTIG
$151
Buy
51.85%
Upside
Reiterated
08/10/26
Oruka Therapeutics: Strong Clinical Momentum and Pipeline Optionality Support Buy Rating and Unchanged $151 Price Target
Guggenheim Analyst forecast on ORKA
Yatin Suneja
Guggenheim
Guggenheim
$200
Buy
101.13%
Upside
Reiterated
08/10/26
Guggenheim Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
Stifel Nicolaus Analyst forecast on ORKA
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$150
Buy
50.84%
Upside
Reiterated
06/29/26
Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)
Leerink Partners Analyst forecast on ORKA
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
SLDBSolid Biosciences
AHCOAdaptHealth
KNSAKiniksa Pharmaceuticals
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oruka Therapeutics

3 Months
Julian HarrisonBTIG
Success Rate
9/11 ratings generated profit
82%
Average Return
+55.31%
Copying Julian Harrison's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +55.31% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
11/12 ratings generated profit
92%
Average Return
+262.19%
Copying David Risinger's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +262.19% per trade.
2 Years
David RisingerLeerink Partners
Success Rate
12/12 ratings generated profit
100%
Average Return
+379.14%
Copying David Risinger's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +379.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ORKA Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
26
24
14
13
13
Buy
10
9
4
7
9
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
33
18
20
22
In the current month, ORKA has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ORKA average Analyst price target in the past 3 months is 154.09.
Each month's total comprises the sum of three months' worth of ratings.

ORKA Financial Forecast

ORKA Earnings Forecast

Next quarter’s earnings estimate for ORKA is -$0.60 with a range of -$0.79 to -$0.32. The previous quarter’s EPS was -$0.55. ORKA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.
Next quarter’s earnings estimate for ORKA is -$0.60 with a range of -$0.79 to -$0.32. The previous quarter’s EPS was -$0.55. ORKA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.
No data currently available

ORKA Sales Forecast

Next quarter’s sales forecast for ORKA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORKA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.
Next quarter’s sales forecast for ORKA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORKA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.

ORKA Stock Forecast FAQ

What is ORKA’s average 12-month price target, according to analysts?
Based on analyst ratings, Oruka Therapeutics’s 12-month average price target is 154.09.
    What is ORKA’s upside potential, based on the analysts’ average price target?
    Oruka Therapeutics has 54.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ORKA a Buy, Sell or Hold?
          Oruka Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Oruka Therapeutics’s price target?
            The average price target for Oruka Therapeutics is 154.09. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $200.00 ,the lowest forecast is $120.00. The average price target represents 54.96% Increase from the current price of $99.44.
              What do analysts say about Oruka Therapeutics?
              Oruka Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of ORKA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.